S
Spiral Therapeutics
Pharmaceutical company developing products for prevention of hearing loss and other inner ear disorders
About Spiral Therapeutics
Spiral Therapeutics, founded in 2016, is a clinical-stage pharmaceutical company dedicated to developing treatments for inner ear disorders, a market with significant unmet needs affecting millions globally. The company was established by Hugo Peris, Justin S. Hanes, and Eugene de Juan. Peris, the CEO, comes from a family with a background in the pharmaceutical industry and holds a Master's in Health Economics and Pharmacoeconomics. Co-founder Justin S. Hanes is an accomplished researcher in nanomedicine and drug delivery, holding professorships at Johns Hopkins University and having co-founded several other biopharmaceutical companies.
The company's core focus is on overcoming the primary challenge of delivering drugs effectively to the inner ear. To address this, Spiral developed the Minimally Invasive Cochlear System (MICS™), a proprietary drug delivery platform. This platform is engineered for the precise, minimally invasive, and long-lasting administration of therapeutic agents directly to the cochlea, allowing for sustained release over weeks or months. The business model centers on advancing its therapeutic pipeline through clinical trials to gain regulatory approval and commercialize its treatments. The company secures funding through venture capital financing, having raised over $24 million from investors such as Catalio Capital Management, Savoir Capital, and Camden Partners to fund its research and development.
Spiral's lead product candidate is SPT-2101, a sustained-release steroid formulation of dexamethasone designed to treat Ménière's disease—a condition causing vertigo, tinnitus, and hearing loss. A key differentiator of SPT-2101 is its application via the MICS™ platform, which ensures the drug is delivered precisely to the round window membrane for extended release. Clinical trials have demonstrated promising results, showing SPT-2101 to be safe and effective in reducing the frequency and severity of vertigo episodes in patients. In 2023, the company strengthened its pipeline by acquiring assets from Otonomy, including data and rights related to other inner ear disorder treatments.
Source: Dealroom company dataNews
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Apr 2026 | $27M | $108M | Ferring Ventures · Advanced Bionics · Uni-Bio Sciences · Gund Investment | ↗ |
| EARLY VC✓Equity / VC | Aug 2023 | — | — | Esperante Ventures · Ferring Ventures | ↗ |
Growth signals
Latest recorded traffic for Spiral Therapeutics is 1.1K monthly website visits, up 32.5% over the last three months. Spiral Therapeutics's team grew 10% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Spiral Therapeutics in the South San Francisco ecosystem
The Spiral Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A11 investors entered at this stage
Camden Partners- SCSavoir Capital
Catalio Capital Management
Inveready
Sunghwan Choi
Humboldt Fund
Esperante Ventures- FVFerring Ventures
- GIGund Investment
Advanced Bionics
Uni-Bio Sciences
Other known investors3 additional known investors
Johns Hopkins University- PAPatrick Aisher
StartX
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Spiral Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Spiral Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









